Lamictal in the Treatment of Post-Herpetic Neuralgia

Stopped early · Phase 2/Phase 3

Conditions studied: Neuralgia, Postherpetic

In brief

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

Key facts

Study ID

NCT00295776

Run by

George Washington University

Starts

2005-02-01

Last updated by the study team

2013-03-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients will be over the age of 18,
• Need to have a diagnosis of Post-Herpetic Neuralgia,
• Minimum of 4 on the Likert Pain Scale,
• If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks

You may not qualify if…

• Currently on any antiepileptic drugs (AED), except for Gabapentin.
• Currently taking opioid or unwilling to washout prior to the study,
• Pregnant and lactating,
• Have active severe systemic disease,
• History of Stevens-Johnson syndrome or TEN,
• Clinically significant abnormal lab values,
• Known drug allergy to Lamictal,
• Patients on Fibrates (Tricor and Lopid),
• History of major psychiatric disturbance and substance abuse.
• Valproate due to increase chances of severe rash,
• Lidocaine Patch,
• Use of hormonal contraceptives (birth control pills, patch, ring, injection)

Where it is running

• Medical Faculty Associates — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.